Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood (2025) 146 (Supplement 1): 927.

https://doi.org/10.1182/blood-2025-927

Published: 2025

Journal Articles

Exploring molecular heterogeneity and clonal evolution in chronic myelomonocytic leukemia via single-cell transcriptome sequencing

Jie Zhou, Yuyuan Huang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2025) 146 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2025-6763

Published: 2025

Journal Articles

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Blood (2025) 146 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2025-6865

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Fen Zhou, Yuhua Li, Ying Wang, Xi Zhang, Jianmin Yang, Xiaobing Huang, JIN WANG, Xianmin Song, Xinsheng Xie, Li Wang, Jie Jin, Liye Zhong, Aibin Liang, Zhenyang Gu, Shengli Xue, Er-Lie Jiang, Baohong Ping, Heng Mei

Blood (2025) 146 (Supplement 1): 6859.

https://doi.org/10.1182/blood-2025-6859

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Blood (2025) 146 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2025-6855

Published: 2025

Journal Articles

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

Lili Zhou, Botao Wang, Ping Li, Yan Lu, Shiguang Ye, Shaoguang Li, Aibin Liang

Blood (2025) 146 (Supplement 1): 7265.

https://doi.org/10.1182/blood-2025-7265

Published: 2025

Journal Articles

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Yuchen Yan, Ligen Liu, Jie Hao, Xiaofeng Han, Ping Li, Libing Wang, Li Yang, Yong Tang, Cheng Wang, Weiyang Liu, Jiayi Ren, Jiong Hu, Jianmin Yang, Qi Zhu, Aibin Liang, Jian Hou, Xianmin Song, Jianqing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6830.

https://doi.org/10.1182/blood-2025-6830

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl

Xiangyu Zhao, Wei Li Zhao, Xiaoxi Zhou, Huilai Zhang, Ting Niu, Hongsheng Zhou, Aibin Liang, Xi Zhang, Meng Lv, Lingshuang Sheng, Na Kuang, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 5931.

https://doi.org/10.1182/blood-2025-5931

Published: 2025

Journal Articles

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Blood (2025) 145 (14): 1526–1535.

https://doi.org/10.1182/blood.2024026401

Published: 2025

Includes: Supplemental data

Journal Articles

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

Baoqing Yang, Jie Zhou, Hao Wu, Shaoguang Li, Aibin Liang, Jianfei Fu

Blood (2024) 144 (Supplement 1): 6702.

https://doi.org/10.1182/blood-2024-202368

Published: 2024

Journal Articles

Optimal Timing and Impact of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult T-Cell Lymphoblastic Lymphoma: Insights from a Large Cohort Multi-Center Real-World Study in Shanghai

Fangfang Yu, Jiahua Niu, Jianmin Yang, Jian Hou, Siguo Hao, Aibin Liang, Hong Xiong, Qi Zhu, Ligen Liu, Jun Shi, Juan Du, Bobin Chen, Rong Wei, Wenli Zhao, Lihua Sun, Yunhua Hou, Rong Tao, Xianmin Song

Blood (2024) 144 (Supplement 1): 7818.

https://doi.org/10.1182/blood-2024-199964

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang

Blood (2024) 144 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2024-208414

Published: 2024

Journal Articles

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Wenbin Qian, Wen Lei, Hui Liu, Wei Chen, Yun Liang, Yi Eve Sun, Xiangmin Tong, Aibin Liang

Blood (2024) 144 (Supplement 1): 7209.

https://doi.org/10.1182/blood-2024-202988

Published: 2024

Journal Articles

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Ping Li, Jian Ge, Shiguang Ye, Lili Zhou, Yiming Gong, Huaying Ruan, Hosein Kouros-Mehr, Aibin Liang

Blood (2024) 144 (Supplement 1): 3475.

https://doi.org/10.1182/blood-2024-199236

Published: 2024

Journal Articles

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Gang An, Zhongxia Huang, Aibin Liang, Baijun Fang, Hongmei Jing, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2024-206742

Published: 2024

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Blood (2024) 144 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2024-199983

Published: 2024

Journal Articles

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Haiyan Jiang, Ping Li, Lili Zhou, Shiguang Ye, Xiu Luo, Yan Lu, Bin Xue, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6934.

https://doi.org/10.1182/blood-2023-188386

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Exploring molecular heterogeneity and clonal evolution in chronic myelomonocytic leukemia via single-cell transcriptome sequencing

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

Optimal Timing and Impact of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult T-Cell Lymphoblastic Lymphoma: Insights from a Large Cohort Multi-Center Real-World Study in Shanghai

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only